Clene Completes FDA-Requested Analyses, Targets Q4 NDA for CNM-Au8 in ALS

What happened

Clene Inc. announced it has completed additional biomarker analyses requested by the FDA and is preparing to submit an NDA for accelerated approval of CNM-Au8 in ALS by Q4 2026. This update follows prior FDA feedback that biomarker and open-label survival data alone were insufficient for accelerated approval, indicating the company has addressed those concerns with new analyses. The company had previously targeted an NDA by end-2025 and a confirmatory Phase 3 contingent on funding; this news suggests a delay to Q4 2026 but a tangible step forward. Financing risk remains acute given a going-concern disclosure and a $2M cash covenant with only $7.3M in cash at Q2 2025. The market will now focus on the FDA's response to the NDA and Clene's ability to secure capital for a potential confirmatory trial.

Implication

While the completion of FDA-requested biomarker analyses is a positive regulatory signal, it does not guarantee accelerated approval; the FDA previously stated that biomarkers and open-label survival data are insufficient alone, and the new analyses may not overcome that hurdle. The shift to a Q4 2026 NDA from the prior end-2025 target implies a delay, potentially reflecting the complexity of the additional analyses or ongoing dialogue. Clene's balance sheet is severely constrained, with going-concern language and a covenant requiring $2M unrestricted cash, leaving little room for error before the NDA submission. Successful acceptance of the NDA and a subsequent non-dilutive financing or partnership would materially de-risk the investment opportunity, but failure to secure funding could force distressed equity raises. Consequently, we maintain a WAIT/NEUTRAL stance until there is clear evidence of FDA support and financial runway, monitoring the Type C meeting outcome and any funding announcements as key triggers.

Thesis delta

The near-term thesis shifts from uncertainty about whether Clene can complete the FDA-requested analyses to uncertainty about whether the completed analyses will be deemed adequate for accelerated approval. While the NDA timeline has slipped from end-2025 to Q4 2026, the company's ability to navigate FDA requests is now demonstrated, partially de-risking execution. However, the core risks—regulatory acceptance and financing—remain unchanged, so the overall stance stays WAIT/NEUTRAL until the FDA weighs in on the completed analyses.